ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ellis L. Jones
Joseph M. Craver
Robert A. Guyton
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duarte, I. G.
Right arrow Articles by Guyton, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duarte, I. G.
Right arrow Articles by Guyton, R. A.

Ann Thorac Surg 1999;68:426-430
© 1999 The Society of Thoracic Surgeons


Original Articles

Treatment of moderate mitral regurgitation and coronary disease by coronary bypass alone: late results

Ignacio G. Duarte, MDa, Yannan Shen, MSa, Malcolm J. MacDonald, MDa, Ellis L. Jones, MDa, Joseph M. Craver, MDa, Robert A. Guyton, MDa

a Carlyle Fraser Heart Center, Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA

Address reprint requests to Dr Guyton, Division of Cardiothoracic Surgery, Department of Surgery, Crawford Long Hospital, Emory University School of Medicine, 550 Peachtree St, NE, Atlanta, GA 30365-2225


    Abstract
 Top
 Abstract
 Introduction
 Patients and methods
 Results
 Comment
 References
 
Background. In cases of moderate mitral regurgitation and coronary artery disease operative strategy continues to be debated between coronary artery bypass grafting alone and concomitant valve replacement or repair. We previously reported on 58 patients with moderate mitral regurgitation who had coronary artery bypass grafting between 1977 and 1983. We present the late results for this original cohort (test group), and a matched control group of coronary artery bypass grafting patients without mitral regurgitation (n = 58).

Methods and Results. In the original cohort, the hospital mortality rate was 3.4% (2 of 58), and 80.4% (45 of 56) of hospital survivors were alive at the time of initial follow-up (mean, 4.3 ± 2.3 years). Hospital mortality in the control group was 6.9% (4 of 58 patients). Follow-up was 98.2% (108 of 110 patients) complete, with a mean follow-up time of 10.3 ± 5.5 years. Kaplan-Meier curves for hospital survivors showed similar 5- and 10-year survival rates between the two groups (p = 0.59). On multivariate analysis, age 65 years or more, congestive heart failure class III or IV, and pulmonary capillary wedge pressure more than 17 mm Hg were significant (p < 0.05) independent predictors of diminished survival in the test group.

Conclusions. Patients with moderate mitral regurgitation and coronary artery disease treated solely with coronary artery bypass grafting had acceptable early and late results. Moderate mitral regurgitation at the time of revascularization does not always warrant operative correction.


    Introduction
 Top
 Abstract
 Introduction
 Patients and methods
 Results
 Comment
 References
 
Patients with coronary artery disease and severe mitral regurgitation (MR) are typically treated with coronary artery bypass grafting (CABG) and concomitant mitral valve replacement or repair [1, 2]. In contrast, patients with mild MR and coronary artery disease are generally offered CABG alone, with acceptable early and late results [2, 3]. The mild degree of concomitant mitral valve dysfunction in this group of patients does not justify the increased operative risks associated with simultaneous mitral valve correction. In addition, there are long-term risks inherent in mitral valve replacement, including anticoagulation for mechanical prostheses and the possibility of bioprosthetic valve degeneration requiring subsequent replacement.

The treatment of moderate mitral regurgitation in association with coronary artery disease however, remains controversial: should CABG alone be used or should CABG and concomitant mitral valve correction be used? In particular, as techniques of valvular repair continue to be refined, many surgeons have advocated mitral valve repair and concomitant CABG for these patients [48]. Others however, have continued to treat these patients with revascularization alone and close postoperative observation of the mitral valve [2, 3].

We previously reported on 58 patients with moderate MR and coronary artery disease treated with CABG alone between 1977 and 1983 [9]. That cohort has remained the largest series of its kind in the literature. The hospital mortality rate was 3.4% (n = 2), and the initial 5-year survival estimate was 77%, with a mean follow-up 4.3 ± 2.3 years. In contrast, 20 patients with moderate MR and coronary artery disease who had combined mitral valve replacement and CABG during a similar time period had a hospital mortality rate of 25% (n = 5), and 5-year survival was limited to approximately 31%. As a result, our institution adopted a policy of treating patients with moderate MR and coronary artery disease with CABG alone.

In this study, we evaluated the long-term results of CABG alone for moderate MR and coronary artery disease by updating the follow-up for the original 58 patients. In addition, we compared these results to those of 58 matched patients with coronary artery disease but without evidence of MR preoperatively who also had CABG during the same time period.


    Patients and methods
 Top
 Abstract
 Introduction
 Patients and methods
 Results
 Comment
 References
 
As described in the original report, patients with moderate MR and coronary artery disease who had CABG between 1977 and 1983 were originally identified from the Emory University Cardiac Data Bank (test group, n = 58) [9]. The data bank was also used to identify patients without preoperative evidence of MR who had CABG during the same time period (control group, n = 58). These control patients were matched to those in the test group on the basis of age, sex, and preoperative ejection fraction, and they were reviewed for follow-up data only.

Moderate mitral regurgitation was defined as 3+ opacification (on a scale of 0 to 4+) of the left atrium during left ventriculography, or complete filling of the left atrium to the same density as the ventricle for two or three cardiac cycles. Patients who had undergone previous mitral valve operation or who required aortic valve operation were excluded. Coronary bypass reoperations and concomitant aneurysmectomy or aneurysm plication were included.

Variables registered
All preoperative data were recorded previously for the 58 original test group patients [9]. Routine demographic data included age, gender, preoperative heart medications, the incidence and number of previous myocardial infarctions, and the occurrence of infarction within 3 months of operation. Symptoms of angina and congestive heart failure were scored according to the Canadian Cardiovascular Society and New York Heart Association classifications [10, 11].

Data obtained from the preoperative cardiac catheterization included ejection fraction and assessment of left ventricular wall motion as normal, hypokinetic, or akinetic. Preoperative pulmonary capillary wedge pressure was also documented.

The cause of MR was determined from historical and physical examination data and the cardiac catheterization. A history of rheumatic fever, a long-standing murmur unrelated to myocardial infarction, and preserved wall motion led to the diagnosis of rheumatic valve disease. Prior myocardial infarction and associated wall motion abnormality suggested an ischemic basis for MR. Prolapse was assumed to be the cause when there was no evidence of rheumatic disease or ischemic etiology. Some patients had MR associated with idiopathic hypertrophic subaortic stenosis, and mixed etiology was assigned in cases where no single cause could be identified.

Follow-up
Follow-up, conducted between January and March 1997, was complete for 98.2% (108 of 110) of all hospital survivors in both groups. Patients were interviewed by telephone. The date and cause of death were noted in cases where the patient had died.

Statistical analysis
Continuous data were displayed as a mean ± standard deviation. The {chi}2 or Fisher’s exact test was used to determine significance of differences for categoric variables, and the t test or Wilcoxon two-sample test was used for continuous variables [12]. Univariate correlates of late survival were identified with the log-rank test, and univariate (unadjusted) Kaplan-Meier curves were derived using S-Plus statistical software (MathSoft, Inc, Seattle, WA) [12]. The multivariate (adjusted) correlates of late survival were identified by Cox proportional hazards regression analysis, where the hazard of death was modeled from all preoperative characteristics identified. The results are given as hazard ratios, ie, ratios of the hazard of death for patients with and without a characteristic present, with 95% confidence intervals. All tests were two-tailed, and a p value of 0.05 or less was considered statistically significant.


    Results
 Top
 Abstract
 Introduction
 Patients and methods
 Results
 Comment
 References
 
Patient demographics and preoperative data are presented in Table 1. With respect to the cause of MR in the test group, ischemia accounted for most (74%) of MR because many patients had prior myocardial infarction (76%) and wall motion abnormalities (71%). Mitral valve prolapse was identified in an additional 16% of cases, idiopathic hypertrophic subaortic stenosis in 3%, rheumatic valve disease in 2%, and 5% of MR cases were of mixed etiology.


View this table:
[in this window]
[in a new window]
 
Table 1. Preoperative Characteristics

 
Early outcome
The hospital mortality rate was 3.4% (2 of 58 patients) in the test group, and 6.9% (4 of 58 patients) in the control group (p > 0.05). Both early deaths in the test group had preoperative ejection fraction less than 0.25 and required preoperative intra-aortic balloon pump counterpulsation.

Follow-up
One hundred ten patients survived the initial hospitalization, and follow-up was complete for 98.2% of all patients (108 of 110). Mean length of follow-up was 10.3 ± 5.1 years in the test group and 10.4 ± 5.9 years in the control group (p = 0.79). Of the hospital survivors, 15 (26%) in the test group and 19 (34%) in the control group were alive at the time of follow-up (p = 0.42). With regard to the cause of death among the deceased patients, there was a larger proportion of cardiac deaths in the test group compared with the control group, 61% versus 30%, respectively. This comparison, however, is limited, as a significantly larger number of deaths in the control group were of undetermined origin, 30% versus 17%, respectively.

Angina and congestive heart failure classification for patients alive at follow-up are shown in Table 2. There was no significant difference in the number of patients with angina or congestive heart failure classification I or II versus III or IV between the two groups. Most patients in both groups who are alive had relatively mild, compensated symptoms.


View this table:
[in this window]
[in a new window]
 
Table 2. Follow-up Findings

 
Five- and 10-year survival rates were 81% and 52%, respectively, in the test group, and 79% and 55% for the control group (p = 0.59). Kaplan-Meier actuarial survival curve for both cohorts are shown in Figure 1. Univariate analysis results with respect to late survival in the test group are shown in Table 3. Female gender (p = 0.15) and myocardial infarction within 3 months before operation (p = 0.69) were not significant predictors of late outcome in these patients. Cause of MR, ischemic versus other, also was not significantly associated with late outcome, (p = 0.24). Multivariate analysis defined pulmonary capillary wedge pressure greater than 17 mm Hg (hazard ratio, 2.28 [1.19, 4.34], p = 0.013), age 65 years or older (hazard ratio 2.14 [1.15, 4.00], p = 0.017), and congestive heart failure classification III or IV (hazard ratio, 3.05 [1.14, 8.15], p = 0.027) as significant independent predictors of late death in the test group of patients. Kaplan-Meier survival curves for the test group of patients with respect to the characteristics found to be significant on multivariate analysis are shown in Figure 2.



View larger version (21K):
[in this window]
[in a new window]
 
Fig 1. Kaplan-Meier actuarial survival curves for the two groups of hospital survivors.

 

View this table:
[in this window]
[in a new window]
 
Table 3. Univariate Correlates of Long-Term Mortality

 


View larger version (24K):
[in this window]
[in a new window]
 
Fig 2. Kaplan-Meier survival curves for hospital survivors in the test group: (A) pulmonary capillary wedge pressure (PCWP); (B) congestive heart failure (CHF) class; and (C) age (in years).

 

    Comment
 Top
 Abstract
 Introduction
 Patients and methods
 Results
 Comment
 References
 
Combined mitral valve and coronary revascularization procedures represent some of the most challenging clinical cases with the highest associated risks [1, 7, 13]. The Coronary Artery Surgery Study reported a 23.7% operative mortality rate for patients who had mitral valve replacement and CABG at 15 centers between 1975 and 1978 [14]. This rate likely reflects the extensive surgical intervention that these critically ill patients had, often with diminished reserves, when myocardial protection strategies were in their infancy. The presence of concomitant mitral insufficiency at the time of revascularization has been correlated with an increased hospital mortality rate [6]. In particular, the severity of mitral insufficiency rather than its absolute presence was shown to be critical in predicting outcome in patients who had an operation [2, 3, 7]. Despite the increased risks, patients with severe MR and coronary artery disease are typically treated with a combined procedure, because their prognosis is poor without concomitant mitral valve correction and revascularization.

The approach to patients with moderate MR and coronary artery disease, however, continues to be debated. Since our initial report of 58 patients with coronary artery disease and moderate MR treated with CABG alone with acceptable early results, we have approached such patients with revascularization alone. Pinson and associates [3] similarly presented good estimated 5-year survival results (72%) for 14 patients with moderate MR treated with CABG alone, but that study was limited by the small sample size and brief follow-up (mean, 3.5 years). The current review evaluated the late survival statistics of our original cohort and assessed the impact on survival of moderate MR left untreated at the time of CABG.

Our 5- and 10-year survival results (81% and 52%, respectively) compared favorably with those of matched patients who had CABG without preoperative MR (control group). The moderate MR treated by CABG alone did not appear to confer an added deleterious risk with respect to late survival. Indeed, it was also similar to previous studies of patients who had CABG and mitral valve repair or replacement. Akins and associates [5] recently reported a 75% 5-year survival rate for 233 patients with MR (all severe cases) treated with mitral valve repair and CABG and 68% survival at 5 years if they had concomitant mitral valve replacement and CABG. Our hospital mortality rate of 3.4% in the test group was significantly less than the 15% rate of He and colleagues [15], who studied 40 patients with moderate MR treated with CABG and mitral valve replacement [15]. In addition, because these patients were treated with CABG alone, they avoided the morbidity associated with anticoagulation for mechanical prostheses or risk of reoperation for bioprosthetic valve degeneration.

With respect to the origin of mitral valve disease, several investigators have found diminished survival in patients treated for ischemic MR and CABG [16, 17]. Those descriptions however, included patients with severe MR and coronary artery disease who clearly were at increased risk of early or late death as previously mentioned. In our cohort of patients with moderate MR, the cause of valvular dysfunction, ischemic versus other, was not a significant independent predictor of outcome.

Multivariate analysis of preoperative demographic and clinical data did identify patients within the test group who were at increased risk of diminished late survival. Elevated pulmonary capillary wedge pressure, increased age, and advanced congestive heart failure classification were the only independent predictors of outcome in this group.

In their review, Rankin and associates [6] called for a more liberal application of mitral valve repair for patients with coronary artery disease and moderate-to-severe MR. This approach subsequently has been supported by several reports describing refinements in the technique of mitral valve repair with improved outcomes [4, 8, 18]. However, several studies have also documented higher early mortality rates among these patients, with limited late survival data. Cohn and colleagues [19] presented a review of 94 patients with ischemic MR who had CABG and mitral valve repair between 1984 and 1994. The operative mortality rate was 9.5%, and the estimated 5-year survival rate was 56% [19]. Our own institution’s preliminary results for combined CABG and mitral valve repair in 164 patients (MR and mitral stenosis), between 1980 and 1996, revealed a hospital mortality rate of 11% among this cohort [20]. As a result of these initial findings, the most common indication for mitral valve repair at our institution remains primarily in cases of myxomatous degeneration of the mitral valve as the cause of severe regurgitation where repair is technically feasible. In cases of coronary artery disease and severe MR, mitral valve replacement is typically offered, although the choice of mitral valve reconstruction versus replacement is at the surgeon’s discretion.

To further place these findings in perspective, 58 individuals were chosen at random from the pool of the general population census in the S-Plus statistical software package (MathSoft, Inc, Seattle, WA). These individuals were matched to the gender and age of patients in the test and control groups at the year of their operation. When the survival curves for these three groups were compared, there was equally diminished late survival in both operative groups compared with the general population, beginning at approximately 8 years after operation (Fig 3). The similar test and control group survival curves suggest that coronary artery disease was the principal cause of their diminished survival and that moderate mitral regurgitation left untreated did not further limit late outcome in the test group.



View larger version (15K):
[in this window]
[in a new window]
 
Fig 3. Comparison of Kaplan-Meier survival curves for the test group and control group of patients as well as that of 58 individuals chosen from the general population and matched for gender and age. Both patient groups revealed an equally diminished late survival compared with that of the general population.

 

    Footnotes
 
This article has been selected for the open discussion forum on the STS Web site: http://www.sts.org/section/atsdiscussion/


    References
 Top
 Abstract
 Introduction
 Patients and methods
 Results
 Comment
 References
 

  1. Cohn L.H., Allred E.N., Cohn L.A., et al. Early and late risk of mitral valve replacement. J Thorac Cardiovasc Surg 1985;90:872-881.[Abstract]
  2. Connolly M.W., Gelbfish J.S., Jacobowitz, et al. Surgical results for mitral regurgitation from coronary artery disease. J Thorac Cardiovasc Surg 1986;91:379-388.[Abstract]
  3. Pinson C.W., Cobanoglu A., Metzdorff M.T., Grunkemeier G.L., Kay P.H., Starr A. Late surgical results for ischemic mitral regurgitation. J Thorac Cardiovasc Surg 1984;88:663-672.[Abstract]
  4. Yun K.L., Miller D.C. Mitral valve repair versus replacement. Cardiac Clinics 1991;9:315-327.
  5. Akins C.W., Hilgenberg A.D., Buckley M.J., et al. Mitral valve reconstruction versus replacement for degenerative or ischemic mitral regurgitation. Ann Thorac Surg 1994;58:668-676.[Abstract/Free Full Text]
  6. Rankin J.S., Hickey M.S., Smith L.R., et al. Current management of mitral valve incompetence associated with coronary artery disease. J Cardiac Surg 1989;4:25-42.[Medline]
  7. Hickey MS, Smith LR, Muhlbaier LH, et al. Current prognosis of ischemic mitral regurgitation. Circulation 1988;78:I51–9.
  8. Bolling S.F., Deeb G.M., Bach D.S. Mitral valve reconstruction in elderly ischemic patients. Chest 1996;109:35-40.[Medline]
  9. Arcidi J.M., Hebeler R.F., Craver J.M., Jones E.L., Hatcher C.R., Guyton R.A. Treatment of moderate mitral regurgitation and coronary disease by coronary bypass alone. J Thorac Cardiovasc Surg 1988;95:951-959.[Abstract]
  10. Campeau L. Grading of angina pectoris [Letter]. Circulation 1976;54:522-523.[Medline]
  11. Criteria Committee of the New York Heart Association, Inc. Diseases of the heart and blood vessels (nomenclature and criteria for diagnosis), 6th ed. Boston: Little, Brown and Company, 1964.
  12. Fisher L.D., Belle G.V. Biostatistics. A methodology for the health sciences. New York: John Wiley, 1993.
  13. Flameng W., Szecsi J., Sergeant P., Daenen W., Herijgers P., Scheys I. Combined valve and coronary artery bypass surgery. Eur J Cardiothorac Surg 1994;8:410-419.[Abstract/Free Full Text]
  14. Czer L.S.C., Gray R.J., DeRobertis M.A., et al. Mitral valve replacement. Circulation 1984;70:I198-I207.
  15. He G.W., Hughes C.F., McCaughan B. Mitral valve replacement combined with coronary artery operation. Ann Thorac Surg 1991;51:916-923.[Abstract/Free Full Text]
  16. Minale C., Messmer B.J. Combination of mitral and coronary artery surgery. J Cardiovasc Surg 1986;27:480-487.[Medline]
  17. Lytle B.W., Cosgrove D.M., Gill C.C., et al. Mitral valve replacement combined with myocardial revascularization. Circulation 1985;71:1179-1190.[Abstract/Free Full Text]
  18. Miller D.C., Stinson E.B., Rossiter S.J., Oyer P.E., Reitz B.A., Shumway N.E. Impact of simultaneous myocardial revascularization on operative risk, functional result, and survival following mitral valve replacement. Surgery 1978;84:848-857.[Medline]
  19. Cohn L.H., Rizzo R.J., Adams D.H., et al. The effect of pathophysiology on the surgical treatment of ischemic mitral regurgitation. Eur J Cardiothorac Surg 1995;9:568-574.[Abstract/Free Full Text]
  20. Craver J.M., Jones E.L., Guyton R.A. Short and long term outcome after mitral valve repair. Circulation 1997;96:I731.
Accepted for publication February 19, 1999.




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
H. Y. Hwang, J. H. Lim, S. J. Oh, J. C. Paeng, and K.-B. Kim
Improved Functional Mitral Regurgitation After Off-Pump Revascularization in Acute Coronary Syndrome
Ann. Thorac. Surg., October 1, 2012; 94(4): 1157 - 1165.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
V. Chan, M. Ruel, and T. G. Mesana
Mitral Valve Replacement Is a Viable Alternative to Mitral Valve Repair for Ischemic Mitral Regurgitation: A Case-Matched Study
Ann. Thorac. Surg., October 1, 2011; 92(4): 1358 - 1366.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. Fattouch, R. Sampognaro, G. Speziale, M. Salardino, G. Novo, M. Caruso, S. Novo, and G. Ruvolo
Impact of Moderate Ischemic Mitral Regurgitation After Isolated Coronary Artery Bypass Grafting
Ann. Thorac. Surg., October 1, 2010; 90(4): 1187 - 1194.
[Abstract] [Full Text] [PDF]


Home page
Heart AsiaHome page
R. Goel, P. P. Sengupta, F. Mookadam, H. P. Chaliki, B. K. Khandheria, and A. J. Tajik
Valvular regurgitation and stenosis: when is surgery required?
Heart Asia, July 5, 2010; 1(1): 20 - 25.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Pocar, D. Passolunghi, A. Moneta, A. Di Mauro, A. Bregasi, R. Mattioli, and F. Donatelli
Baseline left ventricular function and surgical annular stiffening to predict outcome and reverse left ventricular remodeling after undersized annuloplasty for intermediate-degree ischemic mitral regurgitation
J. Thorac. Cardiovasc. Surg., June 1, 2010; 139(6): 1529 - 1538.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Penicka, H. Linkova, O. Lang, R. Fojt, V. Kocka, M. Vanderheyden, and J. Bartunek
Predictors of Improvement of Unrepaired Moderate Ischemic Mitral Regurgitation in Patients Undergoing Elective Isolated Coronary Artery Bypass Graft Surgery
Circulation, October 13, 2009; 120(15): 1474 - 1481.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. V. Badiwala, S. Verma, and V. Rao
Surgical Management of Ischemic Mitral Regurgitation
Circulation, September 29, 2009; 120(13): 1287 - 1293.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
K. Fattouch, F. Guccione, R. Sampognaro, G. Panzarella, E. Corrado, E. Navarra, D. Calvaruso, and G. Ruvolo
POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: A randomized trial
J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 278 - 285.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al.
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation, October 7, 2008; 118(15): e523 - e661.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. B. Prucz, E. S. Weiss, N. D. Patel, L. U. Nwakanma, A. S. Shah, and J. V. Conte
The Impact of Surgical Ventricular Restoration on Mitral Valve Regurgitation
Ann. Thorac. Surg., September 1, 2008; 86(3): 726 - 734.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. M. Calafiore, V. Mazzei, A. L. Iaco, M. Contini, A. Bivona, M. Gagliardi, P. Bosco, S. Gallina, and M. Di Mauro
Impact of Ischemic Mitral Regurgitation on Long-Term Outcome of Patients With Ejection Fraction Above 0.30 Undergoing First Isolated Myocardial Revascularization
Ann. Thorac. Surg., August 1, 2008; 86(2): 458 - 465.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
A. M. Calafiore, A. L. Iaco, M. Contini, A. Bivona, E. Varone, P. Greco, and S. Scandura
Mitral Valve Repair for Ischemic Mitral Regurgitation
Angiology, August 1, 2008; 59(2_suppl): 89S - 92S.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Di Donato, S. Castelvecchio, J. Brankovic, C. Santambrogio, V. Montericcio, and L. Menicanti
Effectiveness of surgical ventricular restoration in patients with dilated ischemic cardiomyopathy and unrepaired mild mitral regurgitation
J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1548 - 1553.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovascular and Thoracic AnnalsHome page
S. Sirivella and I. Gielchinsky
Results of Coronary Bypass and Valve Operations for Mitral Valve Regurgitation
Asian Cardiovascular and Thoracic Annals, October 1, 2007; 15(5): 396 - 404.
[Abstract] [Full Text] [PDF]


Home page
Interact CardioVasc Thorac SurgHome page
A. R. Srivastava, A. Banerjee, S. Jacob, and J. Dunning
Should patients undergoing coronary artery bypass grafting with mild to moderate ischaemic mitral regurgitation also undergo mitral valve repair or replacement?
Interact CardioVasc Thorac Surg, August 1, 2007; 6(4): 538 - 546.
[Abstract] [Full Text] [PDF]


Home page
Interact CardioVasc Thorac SurgHome page
S. Sirivella and I. Gielchinsky
Clinical outcomes of surgery of mitral valve regurgitation and coronary artery bypass grafting
Interact CardioVasc Thorac Surg, August 1, 2006; 5(4): 392 - 397.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D.-H. Kang, M.-J. Kim, S.-J. Kang, J.-M. Song, H. Song, M.-K. Hong, K.-J. Choi, J.-K. Song, and J.-W. Lee
Mitral Valve Repair Versus Revascularization Alone in the Treatment of Ischemic Mitral Regurgitation
Circulation, July 4, 2006; 114(1_suppl): I-499 - I-503.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. A. Grossi, G. A. Crooke, P. L. DiGiorgi, C. F. Schwartz, U. Jorde, R. M. Applebaum, G. H. Ribakove, A. C. Galloway, J. B. Grau, and S. B. Colvin
Impact of Moderate Functional Mitral Insufficiency in Patients Undergoing Surgical Revascularization
Circulation, July 4, 2006; 114(1_suppl): I-573 - I-576.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Di Mauro, G. Di Giammarco, G. Vitolla, M. Contini, A. L. Iaco, A. Bivona, L. Weltert, and A. M. Calafiore
Impact of No-to-Moderate Mitral Regurgitation on Late Results After Isolated Coronary Artery Bypass Grafting in Patients With Ischemic Cardiomyopathy
Ann. Thorac. Surg., June 1, 2006; 81(6): 2128 - 2134.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
G. Fayad, T. Modine, and H. Warembourg
Reply to the Editor
J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1481 - 1482.
[Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
S. Z. Campwala, R. C. Bansal, N. Wang, A. Razzouk, and R. G. Pai
Factors affecting regression of mitral regurgitation following isolated coronary artery bypass surgery
Eur J Cardiothorac Surg, November 1, 2005; 28(5): 783 - 787.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. R. Wong, A. K. Agnihotri, J. W. Hung, G. J. Vlahakes, C. W. Akins, A. D. Hilgenberg, J. C. Madsen, T. E. MacGillivray, M. H. Picard, and D. F. Torchiana
Long-Term Survival After Surgical Revascularization for Moderate Ischemic Mitral Regurgitation
Ann. Thorac. Surg., August 1, 2005; 80(2): 570 - 577.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
S. Z. Campwala, R. C. Bansal, N. Wang, A. Razzouk, and R. G. Pai
Factors affecting regression of mitral regurgitation following isolated coronary artery bypass surgery
Eur J Cardiothorac Surg, July 1, 2005; 28(1): 104 - 108.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
Y.-H. Kim, L. S.C. Czer, H. J. Soukiasian, M. De Robertis, K. E. Magliato, C. Blanche, S. S. Raissi, J. Mirocha, R. J. Siegel, R. M. Kass, et al.
Ischemic Mitral Regurgitation: Revascularization Alone Versus Revascularization and Mitral Valve Repair
Ann. Thorac. Surg., June 1, 2005; 79(6): 1895 - 1901.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
J. Braun, J. J. Bax, M. I. M. Versteegh, P. G. Voigt, E. R. Holman, R. J. M. Klautz, E. Boersma, and R. A. E. Dion
Preoperative left ventricular dimensions predict reverse remodeling following restrictive mitral annuloplasty in ischemic mitral regurgitation
Eur J Cardiothorac Surg, May 1, 2005; 27(5): 847 - 853.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B-K. Lam, A. M. Gillinov, E. H. Blackstone, J. Rajeswaran, B. Yuh, S. K. Bhudia, P. M. McCarthy, and D. M. Cosgrove
Importance of Moderate Ischemic Mitral Regurgitation
Ann. Thorac. Surg., February 1, 2005; 79(2): 462 - 470.
[Abstract] [Full Text] [PDF]


Home page
MMCTSHome page
A. M. Calafiore, M. Di Mauro, M. Contini, L. Weltert, and A. Bivona
Mitral valve repair in ischemic mitral regurgitation
MMCTS, January 1, 2005; 2005(0324): mmcts.2004.000521 - mmcts.2004.000521.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. D. Diodato, M. R. Moon, M. K. Pasque, H. B. Barner, N. Moazami, J. S. Lawton, M. S. Bailey, T. J. Guthrie, B. F. Meyers, and R. J. Damiano Jr
Repair of ischemic mitral regurgitation does not increase mortality or improve long-term survival in patients undergoing coronary artery revascularization: A propensity analysis
Ann. Thorac. Surg., September 1, 2004; 78(3): 794 - 799.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. M. Calafiore, M. Di Mauro, S. Gallina, G. Di Giammarco, A. L. Iaco, G. Teodori, and I. Tavarozzi
Mitral valve surgery for chronic ischemic mitral regurgitation
Ann. Thorac. Surg., June 1, 2004; 77(6): 1989 - 1997.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E. A. Grossi
When should we attempt to make a silk purse from a sow's ear?
J. Thorac. Cardiovasc. Surg., March 1, 2004; 127(3): 618 - 619.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
H. R. Mallidi, M. P. Pelletier, J. Lamb, N. Desai, J. Sever, G. T. Christakis, G. Cohen, B. S. Goldman, and S. E. Fremes
Late outcomes in patients with uncorrected mild to moderate mitral regurgitation at the time of isolated coronary artery bypass grafting
J. Thorac. Cardiovasc. Surg., March 1, 2004; 127(3): 636 - 644.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
P. S. Dahlberg, T. A. Orszulak, C. J. Mullany, R. C. Daly, M. Enriquez-Sarano, and H. V. Schaff
Late outcome of mitral valve surgery for patients with coronary artery disease
Ann. Thorac. Surg., November 1, 2003; 76(5): 1539 - 1548.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. Paparella, L. L. Mickleborough, S. Carson, and J. Ivanov
Mild to moderate mitral regurgitation in patients undergoing coronary bypass grafting: effects on operative mortality and long-term significance
Ann. Thorac. Surg., October 1, 2003; 76(4): 1094 - 1100.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. H. Trichon, D. D. Glower, L. K. Shaw, C. H. Cabell, K. J. Anstrom, G. M. Felker, and C. M. O'Connor
Survival After Coronary Revascularization, With and Without Mitral Valve Surgery, in Patients With Ischemic Mitral Regurgitation
Circulation, September 9, 2003; 108(2011): II-103 - II-110.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. X. Qin, T. Shiota, P. M. McCarthy, C. R. Asher, M. Hail, D. A. Agler, Z. B. Popovic, N. L. Greenberg, N. G. Smedira, R. C. Starling, et al.
Importance of Mitral Valve Repair Associated With Left Ventricular Reconstruction for Patients With Ischemic Cardiomyopathy: A Real-Time Three-Dimensional Echocardiographic Study
Circulation, September 9, 2003; 108(2011): II-241 - II-246.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. M. Harris, T. M. Sundt III, D. Aeppli, R. Sharma, and B. Barzilai
Can late survival of patients with moderate ischemic mitral regurgitation be impacted by intervention on the valve?
Ann. Thorac. Surg., November 1, 2002; 74(5): 1468 - 1475.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. A. Tolis Jr, D. P. Korkolis, G. S. Kopf, and J. A. Elefteriades
Revascularization alone (without mitral valve repair) suffices in patients with advanced ischemic cardiomyopathy and mild-to-moderate mitral regurgitation
Ann. Thorac. Surg., November 1, 2002; 74(5): 1476 - 1481.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Aklog, F. Filsoufi, K. Q. Flores, R. H. Chen, L. H. Cohn, N. S. Nathan, J. G. Byrne, and D. H. Adams
Does Coronary Artery Bypass Grafting Alone Correct Moderate Ischemic Mitral Regurgitation?
Circulation, September 18, 2001; 104(2009): I-68 - I-75.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
T. Ryden, O. Bech-Hanssen, G. Brandrup-Wognsen, F. Nilsson, S. Svensson, and A. Jeppsson
The importance of grade 2 ischemic mitral regurgitation in coronary artery bypass grafting
Eur J Cardiothorac Surg, August 1, 2001; 20(2): 276 - 281.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. Scrofani and C. Antona
Moderate mitral insufficiency in coronary disease: when should it be corrected?
Ann. Thorac. Surg., May 1, 2000; 69(5): 1640 - 1640.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ellis L. Jones
Joseph M. Craver
Robert A. Guyton
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duarte, I. G.
Right arrow Articles by Guyton, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duarte, I. G.
Right arrow Articles by Guyton, R. A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS